Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531030 | 0.88 | ADRB3 (0.38) | ADRB3TDP1L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL2525469 | 0.88 | GPR119 (0.41) | ADRB3CTSSCTSKTDP1L3MBTL1 | |
| SCHEMBL2528609 | 0.87 | L3MBTL1 (0.40) | ADRB3TDP1L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL2530285 | 0.86 | ADRB3 (0.37) | ADRB3TDP1L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL2528091 | 0.85 | ALDH1A1 (0.38) | ADRB3SMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL2529623 | 0.85 | ADRB3 (0.45) | ADRB3TDP1SMN1; SMN2KDM4EGAA | |
| SCHEMBL2529224 | 0.84 | MEN1 (0.42) | SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2529789 | 0.84 | VNN1 (0.41) | ADRB3TDP1L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL2529206 | 0.83 | PPARG (0.41) | ADRB3TDP1SMN1; SMN2KDM4EGAA | |
| SCHEMBL2525560 | 0.82 | L3MBTL1 (0.38) | TDP1L3MBTL1SMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039501-B2 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2011-10-18 | — | — | US | disclosed |
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | CA2 1756/4885CA5A 1707/4885ADRB3 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.